Breaking News Instant updates and real-time market news.

GNMSF

Genmab

, JNJ

Johnson & Johnson

$119.24

0.49 (0.41%)

14:05
10/09/16
10/09
14:05
10/09/16
14:05

Genmab gets FDA priority review for daratumumab in relapsed multiple myeloma

Genmab (GNMSF) announced Friday that the U.S. FDA has granted priority review to the supplemental Biologics License Application for the use of daratumumab in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. The sBLA was submitted by Genmab's licensing partner, Johnson & Johnson's (JNJ) Janssen Biotech. The FDA has assigned a Prescription Drug User Fee Act target date of February 17, 2017 to take a decision on daratumumab in this indication. In addition, the FDA has granted a Standard Review period for the use of daratumumab in combination with pomalidomide and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received at least two prior therapies, with a proteasome inhibitor and an immunomodulatory agent. The PDUFA date for the combination of daratumumab with pomalidomide/dexamethasone is June 17, 2017.

GNMSF

Genmab

JNJ

Johnson & Johnson

$119.24

0.49 (0.41%)

  • 18

    Oct

  • 06

    Nov

GNMSF Genmab

06/21/16
JPMS
06/21/16
INITIATION
JPMS
Neutral
Genmab initiated with a Neutral at JPMorgan
JPMorgan analyst James Quigley started Genmab with a Neutral rating and DK 1,040 price target.
JNJ Johnson & Johnson
$119.24

0.49 (0.41%)

08/24/16
JEFF
08/24/16
NO CHANGE
Target $210
JEFF
Buy
Cooper Companies estimates raised at Jefferies after doctor survey
Jefferies analyst Anthony Petrone reports that the firm's survey of 52 new optometry practices suggest continued gains in dailies and stable share in monthlies for Cooper Companies (COO) and that Johnson & Johnson's (JNJ) Acuvue Vita is off to slow start. Based on the survey results, and a "significant" foreign exchange tailwind, Petrone raised his estimates for Cooper and increased his price target on the shares to $210 from $190. The firm has a Buy rating on Cooper shares.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
09/19/16
LEER
09/19/16
NO CHANGE
LEER
Abbott, Johnson & Johnson transaction positive for both companies, says Leerink
Leerink analyst Danielle Antalffy says the sale of Abbott's (ABT) Medical Optics ophthalmology business to Johnson & Johnson (JNJ) is positive for both companies. The deal strengthens Abbott's balance sheet and eliminates the need for a previously expected $3B capital raise, and adds a key component to Johnson & Johnson's already-strong vision care franchise, the analyst notes.
10/07/16
RBCM
10/07/16
NO CHANGE
RBCM
Johnson & Johnson weakness creates buying opportunity, says RBC Capital
RBC Capital analyst Glenn Novarro says that Johnson & Johnson underperformed the market in Q3 due to a number of factors including Remicade biosimilar risk and the pharma pricing debate. The analyst says that "these concerns are manageable/overblown," and he expects the company to report strong Q3 results, driven by a strong pharma performance. Novoroo expects the company's Q3 revenue to come in slightly above expectations, and he predicts that the company will narrow its 2016 EPS guidance to the high end of the previous range. The analyst recommends buying the stock. He keeps a $133 price target and Outperform rating on the shares.

TODAY'S FREE FLY STORIES

09:05
09/20/17
09/20
09:05
09/20/17
09:05
General news
U.S. equities are stuck in the Fed's headlights »

U.S. equities are stuck…

SGMS

Scientific Games

$43.10

1.05 (2.50%)

09:04
09/20/17
09/20
09:04
09/20/17
09:04
Hot Stocks
Scientific Games to acquire NYX Gaming Group for C$2.40 per share »

Scientific Games and NYX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

PG

Procter & Gamble

$94.17

1.02 (1.10%)

09:04
09/20/17
09/20
09:04
09/20/17
09:04
Hot Stocks
Trian: Initiatives will make P&G 'best-in-class company once again' »

Trian Fund Management,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$52.09

-4.48 (-7.92%)

09:03
09/20/17
09/20
09:03
09/20/17
09:03
Recommendations
Portola Pharmaceuticals analyst commentary  »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

RCII

Rent-A-Center

$12.16

-0.05 (-0.41%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Hot Stocks
Breaking Hot Stocks news story on Rent-A-Center »

Rent-A-Center says August…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEO

American Eagle

$13.63

0.18 (1.34%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Hot Stocks
American Eagle to expand to India through licensed stores »

American Eagle Outfitters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOGL

Alphabet Class A

$936.86

7.11 (0.76%)

, GOOG

Alphabet

$921.81

6.81 (0.74%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Periodicals
Google said to acquire certain HTC assets, VentureBeat's Bass reports »

VentureBeat reporter Evan…

GOOGL

Alphabet Class A

$936.86

7.11 (0.76%)

GOOG

Alphabet

$921.81

6.81 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Nov

RCII

Rent-A-Center

$12.16

-0.05 (-0.41%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Hot Stocks
Rent-A-Center reports core U.S. SSS down 5.3% in August »

Rent-A-Center, announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEET

Meet Group

$3.84

-0.09 (-2.29%)

09:01
09/20/17
09/20
09:01
09/20/17
09:01
Conference/Events
Meet Group to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

EDVMF

Endeavour Mining

$18.42

-0.0721 (-0.39%)

09:00
09/20/17
09/20
09:00
09/20/17
09:00
Conference/Events
Endeavour Mining holds a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

08:57
09/20/17
09/20
08:57
09/20/17
08:57
Hot Stocks
General Mills says cereal sales improved in August »

Expects to improve yogurt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

CIEN

Ciena

$22.08

-0.26 (-1.16%)

08:57
09/20/17
09/20
08:57
09/20/17
08:57
Recommendations
Ciena analyst commentary  »

Ciena FY18 growth more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

FDX

FedEx

08:57
09/20/17
09/20
08:57
09/20/17
08:57
Recommendations
FedEx analyst commentary  »

FedEx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

BPMC

Blueprint Medicines

$63.86

0.98 (1.56%)

08:56
09/20/17
09/20
08:56
09/20/17
08:56
Recommendations
Blueprint Medicines analyst commentary  »

Blueprint Medicines price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$24.86

0.16 (0.65%)

, S

Sprint

$8.20

0.52 (6.77%)

08:55
09/20/17
09/20
08:55
09/20/17
08:55
Options
Notable open interest changes for September 20th »

Tuesday's total…

BAC

Bank of America

$24.86

0.16 (0.65%)

S

Sprint

$8.20

0.52 (6.77%)

T

AT&T

$38.21

0.79 (2.11%)

BABA

Alibaba

$180.07

0.09 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 02

    Oct

  • 22

    Oct

  • 29

    Nov

  • 16

    May

RARE

Ultragenyx

$51.90

-1.09 (-2.06%)

08:54
09/20/17
09/20
08:54
09/20/17
08:54
Conference/Events
Ultragenyx has a conference call hosted by JPMorgan »

JPMorgan Analyst Kasimov…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 16

    Nov

WBC

Wabco

$146.87

3.9 (2.73%)

08:53
09/20/17
09/20
08:53
09/20/17
08:53
Conference/Events
Wabco holds a conference call »

Chairman & CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$156.60

0.83 (0.53%)

08:53
09/20/17
09/20
08:53
09/20/17
08:53
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AAN

Aaron's

$39.35

0.94 (2.45%)

08:49
09/20/17
09/20
08:49
09/20/17
08:49
Recommendations
Aaron's analyst commentary  »

Aaron's weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

08:49
09/20/17
09/20
08:49
09/20/17
08:49
Recommendations
Bed Bath & Beyond analyst commentary  »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

08:45
09/20/17
09/20
08:45
09/20/17
08:45
Earnings
General Mills says sees FX having 1c favorable impact to FY18 EPS 

FY18 EPS consensus $3.10.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

RSX

Market Vectors Russia ETF

$21.74

0.08 (0.37%)

, TQQQ

ProShares UltraPro QQQ

$115.32

0.49 (0.43%)

08:45
09/20/17
09/20
08:45
09/20/17
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

RSX

Market Vectors Russia ETF

$21.74

0.08 (0.37%)

TQQQ

ProShares UltraPro QQQ

$115.32

0.49 (0.43%)

FSLR

First Solar

$48.86

0.32 (0.66%)

IMMU

Immunomedics

$11.64

0.38 (3.37%)

JCP

J.C. Penney

$3.97

-0.18 (-4.34%)

IYR

DJ US Real Estate Index Fund

$81.01

-0.63 (-0.77%)

CHK

Chesapeake

$4.04

-0.01 (-0.25%)

SMH

Market Vectors Semiconductor

$92.60

0.24 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 27

    Sep

  • 02

    Oct

FDX

FedEx

$216.00

0.92 (0.43%)

08:43
09/20/17
09/20
08:43
09/20/17
08:43
Technical Analysis
Technical View: FedEx trades lower after results and outlook »

Shares were last at $213…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

08:43
09/20/17
09/20
08:43
09/20/17
08:43
Recommendations
Gemphire Therapeutics analyst commentary  »

Gemphire data support…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FDX

FedEx

$216.00

0.92 (0.43%)

08:42
09/20/17
09/20
08:42
09/20/17
08:42
Recommendations
FedEx analyst commentary  »

FedEx price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.